Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) EBT (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported EBT over the past 16 years, most recently at -$1.1 million for Q2 2025.

  • For Q2 2025, EBT rose 84.4% year-over-year to -$1.1 million; the TTM value through May 2025 reached -$38.7 million, down 506.5%, while the annual FY2025 figure was -$38.7 million, 506.5% down from the prior year.
  • EBT for Q2 2025 was -$1.1 million at Lifecore Biomedical, Inc. \De\, up from -$14.8 million in the prior quarter.
  • Over five years, EBT peaked at $15.0 million in Q1 2024 and troughed at -$36.8 million in Q2 2023.
  • A 5-year average of -$8.5 million and a median of -$8.4 million in 2022 define the central range for EBT.
  • Biggest five-year swings in EBT: crashed 8527.43% in 2021 and later surged 254.15% in 2023.
  • Year by year, EBT stood at $1.3 million in 2021, then tumbled by 823.03% to -$9.2 million in 2022, then surged by 254.15% to $14.2 million in 2023, then crashed by 146.05% to -$6.5 million in 2024, then skyrocketed by 82.94% to -$1.1 million in 2025.
  • Business Quant data shows EBT for LFCR at -$1.1 million in Q2 2025, -$14.8 million in Q1 2025, and -$6.5 million in Q4 2024.